07:00 , Jul 27, 2015 |  BC Week In Review  |  Company News

Omeros, Fagron deal

Omeros granted Fagron exclusive rights to commercialize OMS103 in the U.S. Fagron will pay Omeros a majority share of gross revenue from sales plus a minimum revenue per vial sold. Omeros is eligible for up...
08:00 , Jan 7, 2013 |  BC Week In Review  |  Clinical News

OMS103HP: Phase III data

A double-blind, U.S. Phase III trial in 344 patients undergoing arthroscopic partial meniscectomy surgery showed that OMS103HP missed the primary endpoint of improving knee symptoms as measured by the change from baseline in the Symptoms...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

4Q Stock Wrap-Up: Go big or go home

Large cap biotechs were the only market cap segment to end 4Q12 in the black, finishing up 1% to post a 26% gain on the year. Small caps brought up the rear in 4Q, but...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) was off $0.80 to $24.91 Christmas week after FDA approved Juxtapid lomitapide to treat patients with homozygous familial hypercholesterolemia (hoFH). Juxtapid was approved with a REMS and a boxed...
00:48 , Dec 28, 2012 |  BC Extra  |  Top Story

OMS103HP misses Phase III endpoint

Omeros Corp. (NASDAQ:OMER) said OMS103HP missed the primary endpoint of improving knee symptoms from baseline to day 30 vs. vehicle irrigation solution in a Phase III trial of the product to improve post-operative joint function...
07:00 , Oct 1, 2012 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Back in black

Large cap biotechs stormed back after a weak 2Q12 to post a 7% gain for a third quarter in which every market cap segment finished in the black, albeit just barely for the micro-caps. For...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Clinical News

OMS103HP: Completed Phase III enrollment

Omeros completed enrollment in a double-blind, placebo-controlled Phase III trial evaluating OMS103HP in about 330 patients undergoing arthroscopic partial meniscectomy surgery. The company plans to start a second double-blind, placebo-controlled Phase III trial in the...
07:00 , Jul 2, 2012 |  BioCentury  |  Finance

3Q Financial Markets Preview: Miles of milestones

A deep line-up of milestones could help retain gains the sector has been holding onto since 1Q12. In particular, investors would love to see further breakthroughs in difficult areas such as Alzheimer's disease and obesity....
08:00 , Jan 9, 2012 |  BioCentury  |  Finance

PDUFAs produce yawns

Stephen Hansen Senior Writer  There are more than twice as many PDUFA dates this year than last - at least 40 vs. 17 - but only a handful of potential approvals are drumming up interest...
08:00 , Dec 12, 2011 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/9 cls Omeros Corp. (NASDAQ:OMER) Rodman Elemer Piros Upgrade Market outperform (from market perform) 3% $4.04 Piros also set a $13 target ahead of...